Content area
Full Text
Welcome to this week's FiercePharmaAsia report, which includes stories about the U.K. government's request for information on third-party advisers involved in GlaxoSmithKline's China bribery scandal, several Anglo-Sino biopharma deals signed during U.K. Prime Minister Theresa May's state visit to China, Samsung BioLogics' 2017 sales growth, and more.
1. GlaxoSmithKline notifies SEC, DOJ of new questions in China bribery probe
About five years have passed since the China bribery scandal emerged, and it is still haunting GlaxoSmithKline today. The drugmaker revealed that the U.K.’s Serious Fraud Office is asking for information on “third-party advisers engaged by the company.” One known adviser was a husband-and-wife private detective team, who ended up in prison in China.
2. AstraZeneca allies with Alibaba and Tencent as its China sales soar
As CEO Pascal Soriot accompanied U.K. Prime Minister Theresa May on her visit to China, AstraZeneca inked two deals focused on smart health services with Chinese internet giants Alibaba and Tencent. It also came...